Bone tissue growth enhancement by calcium phosphate coatings on porous titanium alloys: the effect of shielding metal dissolution product.
The possible mechanism of minimization of prosthesis-derived bone growth inhibitors by shielding of the metal and the reduction, if not elimination, of the associated metal dissolution was investigated. Titanium, aluminium and vanadium release rates were determined in vitro for Ti alloy specimens both with and without a calcium phosphate coating. Ti orderly oriented wire mesh (OOWM) porous coatings on Ti-6Al-4V substrates were used as the metal specimens. Half of the specimens were coated with a 75 microns calcium phosphate ceramic (CPC coating). Seven reference (OOWM) and seven coated (OOWM-CPC) specimens were immersed and placed along with seven control solutions for various periods in an incubator maintained at 37 degrees C and 5% CO2 - air atmosphere. Whereas the reference solutions showed a Ti release increasing as a function of time, the solutions that had the CPC-coated specimens contained no measurable amounts of titanium. The Al in solution around the CPC-coated specimens was significantly greater than the concentration around non-coated specimens. The Al, however, did not increase significantly with time, at least up to 4 wk immersion. The ceramic coating had a small beneficial effect on V concentration. In the absence of a significant adverse effect of Ti on local bone tissue formation, we focus on the Al data of our study. The possible adverse effect of this element is well documented. The calcium phosphate coating produced a significant increase of biological fixation, yet at the same time a greater Al release into solution, calling into question the significance of CPC coating in shielding adverse metal passive dissolution to explain enhanced bone growth [corrected].
Ducheyne
P
P
Department of Bioengineering, University of Pennsylvania, Philadelphia 19104.
Bianco
P D
PD
Kim
C
C
D000497:Alloys / Q000378:metabolism; D000535:Aluminum / Q000009:adverse effects / Q000378:metabolism; D001672:Biocompatible Materials / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D001846:Bone Development / Q000187:drug effects*; D002130:Calcium Phosphates / Q000494:pharmacology*; D019736:Prostheses and Implants; D013499:Surface Properties; D014025:Titanium / Q000378:metabolism; D014639:Vanadium / Q000009:adverse effects / Q000378:metabolism
D000497:Alloys; D001672:Biocompatible Materials; D002130:Calcium Phosphates; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; D014639:Vanadium; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; D000535:Aluminum; D014025:Titanium; C485829:calcium phosphate, dibasic, anhydrous